ADHERENCE TO AISF RECOMMENDATIONS FOR INTEGRATED MANAGEMENT OF HEPATOCELLULAR CARCINOMA IN A REAL-WORLD CLINICAL PRACTICE

被引：0
|
作者：
Piai, G. [1 ]
Messina, V. [2 ]
Valente, G. [1 ]
Rinaldi, L. [1 ]
Moggio, G. [3 ]
机构：
[1] AORN St Anna & San Sebastiano, UOSD Fisiol Epat Con Serv Assistenza Trapiantandi, Caserta, Italy
[2] AORN St Anna & San Sebastiano, UOS Ottimizzaz & Monitoraggio Epatiti Croniche Vi, Caserta, Italy
[3] AORN St Anna & San Sebastiano, UOSD Radiol Interventist, Caserta, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2015年 / 47卷
关键词：
D O I：
10.1016/j.dld.2015.01.058
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
T-15
引用
收藏
页码：E25 / E25
页数：1
相关论文
共 50 条
  • [1] Assessment of adherence to skincare recommendations in clinical practice: a real-world observational study
    Rakita, U.
    Kaundinya, T.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E172 - E173
  • [2] Assessment of adherence to skin care recommendations in clinical practice: A real-world observational study
    Rakita, Uros
    Kaundinya, Trisha
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) : 1141 - 1143
  • [3] Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
    Wang, Shen -Yung
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (02) : 349 - 351
  • [4] Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
    Iwamoto, Hideki
    Shimose, Shigeo
    Noda, Yu
    Shirono, Tomotake
    Niizeki, Takashi
    Nakano, Masahito
    Okamura, Shusuke
    Kamachi, Naoki
    Suzuki, Hiroyuki
    Sakai, Miwa
    Kajiwara, Akira
    Itano, Satoshi
    Tanaka, Masatoshi
    Yamaguchi, Taizo
    Kuromatsu, Ryoko
    Koga, Hironori
    Torimura, Takuji
    CANCERS, 2021, 13 (11)
  • [5] INITIAL EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE
    Iwamoto, Hideki
    Shimose, Shigeo
    Takashi, Niizeki
    Noda, Yu
    Shirono, Tomotake
    Nakano, Masahito
    Okamura, Shusuke
    Kamachi, Naoki
    Suzuki, Hiroyuki
    Kuromatsu, Ryoko
    Koga, Hironori
    Torimura, Takuji
    HEPATOLOGY, 2021, 74 : 652A - 652A
  • [6] Real-world evidence in hepatocellular carcinoma
    Mospan, Andrea R.
    Morris, Heather L.
    Fried, Michael W.
    LIVER INTERNATIONAL, 2021, 41 : 61 - 67
  • [7] Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real-world practice
    Shimose, Shigeo
    Saeki, Issei
    Tomonari, Tetsu
    Ito, Takanori
    Tani, Joji
    Takeuchi, Yasuto
    Yoshioka, Naoki
    Naito, Takehito
    Takeuchi, Mamiko
    Kakizaki, Satoru
    Hatanaka, Takeshi
    Sasaki, Kyo
    Yasunaka, Tetsuya
    Sakata, Masahiro
    Iwamoto, Hideki
    Itano, Satoshi
    Shirono, Tomotake
    Tanabe, Norikazu
    Yamamoto, Takafumi
    Naganuma, Atsushi
    Nishina, Soji
    Otsuka, Motoyuki
    Kawashima, Hiroki
    Takayama, Tetsuji
    Takami, Taro
    Kawaguchi, Takumi
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [8] Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
    Singal, Amit G.
    Nagar, Saurabh P.
    Hitchens, Abby
    Davis, Keith L.
    Iyer, Shrividya
    CANCER REPORTS, 2023, 6 (01)
  • [9] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
  • [10] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
12345